Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Harvard Business School
Daiichi Sankyo
UBS
Federal Trade Commission

Generated: August 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,299,209

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,299,209 protect, and when does it expire?

Patent 8,299,209 protects SIGNIFOR and is included in one NDA.

This patent has forty-one patent family members in thirty-four countries.

Summary for Patent: 8,299,209
Title:Pharmaceutical composition comprising cyclic somatostatin analogues
Abstract: Pharmaceutical compositions comprising a somastatin analogue in the form of a liquid formulation for parenteral administration are disclosed.
Inventor(s): Lambert; Olivier (Spechbach-le-Haut, FR), Moser; Katrin (Brookline, MA)
Assignee: Novartis AG (Basel, CH)
Application Number:12/359,527
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,299,209

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis SIGNIFOR pasireotide diaspartate SOLUTION;SUBCUTANEOUS 200677-001 Dec 14, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis SIGNIFOR pasireotide diaspartate SOLUTION;SUBCUTANEOUS 200677-002 Dec 14, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis SIGNIFOR pasireotide diaspartate SOLUTION;SUBCUTANEOUS 200677-003 Dec 14, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,299,209

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0314695.8Jun 24, 2003
United Kingdom0325388.7Oct 30, 2004

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
Covington
Harvard Business School
Chubb
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.